US Stock Market Move | Afektei tablets approved for listing, Cytokinetics (CYTK.US) surges over 10%

On Monday, Cytokinetics (CYTK.US) surged over 10%, hitting a new high for the year, now trading at $69.34. In terms of news, the National Medical Products Administration recently approved Cytokinetics, Incorporated's application for the innovative drug Afcetinib tablets (trade name: Xingshuping) to be listed through the priority review and approval procedure. This drug is used to treat obstructive hypertrophic cardiomyopathy (HCM) in adult patients classified as New York Heart Association (NYHA) functional class II-III, to improve exercise capacity and symptoms.